[1] Wang L, Yu WF. Obstructive jaundice and perioperative management. Acta anaesthesiologica Taiwanica, 2014, 52: 22-29. [2] Tan DW, Fu Y, Su Q, et al. Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis. Sci Rep, 2016, 6: 33789. [3] Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, et al. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Brit J Cancer, 2013, 109: 24-28. [4] Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420: 860-867. [5] Jin H, Pang Q, Liu H, et al. Prognostic value of inflammation-based markers in patients with recurrent malignant obstructive jaundice treated by reimplantation of biliary met al stents: A retrospective observational study. Medicine, 2017, 96: e5895. [6] Yao D, Kunam VK, Li X. A review of the clinical diagnosis and therapy of cholangiocarcinoma. J Int Med Res, 2014, 42: 3-16. [7] Choi JM, Kim JH, Kim SS, et al. A comparative study on the efficacy of covered met al stent and plastic stent in unresectable malignant biliary obstruction. Clin Endoscopy, 2012, 45: 78-83. [8] Maluf-Filho F, Retes FA, Neves CZ, et al. Transduodenal endosonography-guided biliary drainage and duodenal stenting for palliation of malignant obstructive jaundice and duodenal obstruction. JOP Pancreas, 2012, 13: 210-214. [9] Pan H, Liang Z, Yin TS, et al. Hepato-biliary-enteric stent drainage as palliative treatment for proximal malignant obstructive jaundice. Med Oncol, 2014, 31: 853. [10] Soares KC, Kamel I, Cosgrove DP, et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobil Surg Nutr, 2014, 3: 18-34. [11] Ha H, Nam AR, Bang JH, et al. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget, 2016, 7: 76604-76612. [12] Lolli C, Caffo O, Scarpi E, et al. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Frontiers in Pharmacology, 2016, 7: 376. [13] Yang HB, Xing M, Ma LN, et al. Prognostic significance of neutrophil-lymphocyteratio/platelet-lymphocyteratioin lung cancers: a meta-analysis. Oncotarget, 2016, 7: 76769-76778. [14] Xu X, Chen W, Zhang L, et al. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin MedJ, 2014, 127: 4204-4209. [15] Carr BI, Cavallini A, D'Alessandro R, et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer, 2014, 14: 43. [16] Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semi Thromb Hemosta, 2004, 30: 95-108. [17] Buergy D, Wenz F, Groden C, et al. Tumor-platelet interaction in solid tumors. Int J Cancer J Int Cancer, 2012, 130: 2747-2760. [18] Iwase R, Shiba H, Haruki K, et al. Post-operative lymphocyte count may predict the outcome of radical resection for gallbladder carcinoma. Anticancer Res, 2013, 33: 3439-3444. [19] Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochimica et biophysica acta, 1988, 948: 151-173. [20] Ren QQ, Fu SJ, Zhao Q, et al. Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation. Tumour biol, 2016, 37: 8973-8978. [21] Sasaki A, Iwashita Y, Shibata K, et al. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery, 2006, 139: 755-764. |